Senators reintroduce telehealth bill to give seniors more access to mental health services
By
Aaron Dorman
Feb 01, 2024
A bipartisan group of senators have reintroduced a bill to remove current restrictions on telehealth mental health services for seniors.
Biogen cuts price of controversial Aduhelm in half
Dec 21, 2021
The drug shows promise in clearing the brain plaques believed to play a role in Alzheimer’s disease.
Medicare mulls coverage for controversial drug for Alzheimer’s disease
Jul 13, 2021
CMS says a final decision on coverage is not likely until next spring.
Medicare will cover new class of Alzheimer’s drugs if fully approved by FDA, with limits
Jun 02, 2023
Drug makers also will have to gather and keep data in a registry showing how the drugs are working in the real world.
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.
Medicare monthly premiums to drop for seniors
Sep 28, 2022
The fee cuts come at the same time as seniors receive a Social Security cost-of-living increase for 2023 of up to 9 or 10%.
Geriatrician calls for move to value-based care model for home care
By
Diane Eastabrook
Apr 19, 2021
Medicare and private insurers must quickly transition to a value-based-care payment model to meet the needs of an aging population, the head of Geriatric Medicine at the University of Virginia (UVA) told...
Hearing aid manufacturers still need to listen up about seniors’ specific needs: report
By
Aaron Dorman
Mar 05, 2024
Many seniors could benefit from larger, more customized hearing aids, which are easier to manipulate, experts noted.
Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Medicare may rethink premium hike for pricey Alzheimer’s drug
Jan 10, 2022
The announcement comes shortly after Aduhelm maker Biogen cut the price of the drug by about half, from $56,000 to $28,000 a year.